Premium
Bioequivalence of two pharmaceutical forms of diltiazem
Author(s) -
Rubio Modesto,
Masana Mónica I.,
Garcilazo Enrique,
de Los Santos Antonio R.,
di Girolamo Guillermo
Publication year - 1990
Publication title -
biopharmaceutics and drug disposition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.419
H-Index - 58
eISSN - 1099-081X
pISSN - 0142-2782
DOI - 10.1002/bdd.2510110108
Subject(s) - diltiazem , bioavailability , bioequivalence , pharmacology , pharmacokinetics , coronary heart disease , nifedipine , dosage form , coronary vasodilator , medicine , chemistry , vasodilation , calcium
Diltiazem, a calcium‐channel blocking agent, has been shown to be a potent coronary vasodilator used in the treatment of ischaemic heart disease. The present study was conducted to compare the bioavailability of regular 60 mg tablets administered every 6 h with sustained release capsules of 120 mg administered every 12 h. High‐performance liquid chromatographic analysis was carried out for determination of diltiazem and one of its metabolites desacetildiltiazem in six male patients. The relative bioavailability of this sustained‐release pharmaceutical form did not show any significant difference with that of tablets.